Integrated Multi-omics Data for Personalized Treatment of Obesity-associated Fatty Liver Disease

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorInstitut Investigacio Sanitaria Pere Virgili

About this trial

The investigators seek to analyze the samples provided by patients with obesity-associated fatty liver disease at the multi-omics level and to integrate the results with clinical information, genotypic variants, and factors influencing inter-organ crosstalk. The main aim is to improve the interpretation of fatty liver disease associated with obesity and diabetes by developing predictive models built with algorithms from artificial intelligence. The challenge is to decipher the flow of information by exploring contributing factors, proximate causes of regulatory defects, and maladaptive responses that may promote therapeutic approaches.

Eligibility criteria

Qualifiers

Body mass index greater or equal to 40 kg/m².

Body mass index between 35 and 40 kg/m² with high-risk comorbidities (diagnosis or treatment for hypertension, dyslipidemia, or type 2 diabetes mellitus).

Positive psychiatric evaluation.

Age greater or equal to 18 years old.

Disqualifiers

Legal or illegal drug consumption, including alcohol.

Diagnosis of Hepatitis.

Current cancer diagnosis or treatment.

Clinical or analytical evidence of severe illness.

Trial design

Treatments tested in this trial

  • To propose diagnostic tests for liver diseases before surgical decisions.

Treatment groups

1,104 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Institut Investigacio Sanitaria Pere Virgili

Lead sponsor

Hospital Universitari Sant Joan

Collaborator

La Caixa Foundation

Collaborator

Instituto de Salud Carlos III

Collaborator

University of Barcelona

Collaborator